Anaphylaxis: Difference between revisions

No edit summary
Line 37: Line 37:


==Presentation==
==Presentation==


* Cutaneous symptoms - 90%
* Cutaneous symptoms - 90%
Line 43: Line 42:
* GI symptoms - 40%
* GI symptoms - 40%
* Cardiovascular symptoms - 35%  
* Cardiovascular symptoms - 35%  
  ==Treatment ==
  ==Treatment ==


* Epinephrine 1:1000 IM 0.3-0.5mg (0.3-05mL) Q5-15min  
* Epinephrine 1:1000 IM 0.3-0.5mg (0.3-05mL) Q5-15min  
Line 66: Line 65:
*  Methylprednisolone 125 mg IV
*  Methylprednisolone 125 mg IV
* Three day PO course (biphasic reaction always occurs within 72hrs)
* Three day PO course (biphasic reaction always occurs within 72hrs)


==Course==
==Course==

Revision as of 00:51, 2 March 2011

Definition

  • Highly likely when ANY ONE of the following criteria is fulfilled:
  • Criterion 1 (90% of pts)
  • Acute onset of an illness involving the skin, mucosal tissue, or both AND at least one of the following:
  • Respiratory compromise
  • Reduced BP or associated symptoms (syncope, dizziness)
  • Criterion 2 (10-20% of pts)
  • TWO OR MORE of the following that that occur rapidly after exposure to a LIKELY allergen for that pt
  • Involvement of the skin-mucosal tissue (hives, swollen lips-tongue-uvula)
  • Respiratory compromise
  • Reduced BP or associated symptoms
  • Persistent GI symptoms (vomiting, diarrhea, crampy abd pain)
  • Criterion 3
  • Reduced BP after exposure to a KNOWN allergy for that pt (minutes to hours):
  • Adults
  • Systolic < 90 or > 30% from baseline
  • Peds
  • Less than 70 mmHg from 1 month up to 1 year
  • Less than (70 mmHg + [2 x age]) from 1 to 10 years
  • Less than 90 mmHg from 11 to 17 years

DDX

  • Generalized urticaria
  • Angioedema
  • Asthma exacerbation
  • Anxiety attack
  • MI
  • Scombroidosis
  • Other forms of shock


Presentation

  • Cutaneous symptoms - 90%
  • Respiratory symptoms - 70%
  • GI symptoms - 40%
  • Cardiovascular symptoms - 35%
==Treatment ==
  • Epinephrine 1:1000 IM 0.3-0.5mg (0.3-05mL) Q5-15min
  • Always IM initially
  • Start epinephrine infusion 1:10,000 2-10µg/min if inadequate response to IM
  • PEDS
  • IM - 0.01mg/kg/dose (max 0.5mg)
  • IV infusion - 0.05-1 mcg/kg/min
  • Oxygen
  • NS bolus
  • If unresponsive to Epi must assume pt to be severely intravascularly depleted
  • Supine positioning
  • Glucagon 1-2mg IV over 5 min, followed by infusion of 5-15µg/min (if on B-blocker AND unresponsive to epi)
  • Also consider:
  • Albuterol: For bronchospasm resistant to IM epinephrine
  • Antihistamines
  • Only for sympton control (hives, itching) AFTER hemodynamically stable
  • Diphenhydramine 25 to 50 mg IV
  • Ranitidine 50 mg IV (minimal evidence to support this)
  • Glucocorticoid: May blunt biphasic reaction
  • Methylprednisolone 125 mg IV
  • Three day PO course (biphasic reaction always occurs within 72hrs)

Course

  • Uniphasic (80-90%)
  • Symptoms peak within 30min-1hr after onset, resolves within 30min-1hr of receiving Tx
  • Biphasic (10-20%)
  • Uniphasic response, followed by asymptomatic period of hour or more, then return of symptoms
  • The second phase does not necessarily resemble the first!
  • Possible risk factors
  • Severe initial symptoms
  • Late administration of epi
  • Delayed resolution of initial symptoms
  • Little evidence that glucocorticoids blunt a biphasic presentation
  • Protracted (case reports)
  • Lasts hours to days without resolving completely


Disposition

  • Admit: Severe and moderate (especially if symptoms did not respond promptly to epi)
  • Home: Anaphylaxis that responded promptly after ED observation
  • Send home with an epi autoinjector!

Sources

  • Tintinalli
  • Brown SGA, Mullins RJ and Gold MS, Anaphylaxis: diagnosis and management, MJA 2006; 185: 283–289
  • Ewan PW, ABC of allergies – Anaphylaxis, BMJ 1998; 316: 1442-1445
  • Simons FER, Gu X, Simons KJ, Epinephrine absorption in adults: Intramuscular versus subcutaneous injection, J Allergy Clin Immunol 2001;108:871-3
  • Lieberman P et al, The diagnosis and management of anaphyalxis: An updated practice parameter, J Allergy Clin Immunol 2005;115;3:S483-S523
  • Sheikh A, Shehata YA, Brown SGA, Simons FER. Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock.Cochrane Database of Systematic Reviews2008, Issue 4. Art. No.: CD006312. DOI:10.1002/14651858.CD006312.pub2.
  • Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.